The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•26 February 2026•

1 min read

atai Life Sciences Announces Positive Phase 2a Results for Social Anxiety Drug EMP-01

Key Facts

1EMP-01 met primary safety and tolerability objectives in a Phase 2a trial for Social Anxiety Disorder.

2The drug demonstrated an 11.85 point reduction on the Liebowitz Social Anxiety Scale (LSAS) compared to placebo.

atai Life Sciences has announced positive topline results from its Phase 2a clinical trial of EMP-01, an oral R-MDMA derivative designed to treat Social Anxiety Disorder. The study successfully met its primary objectives for safety and tolerability, showing that the drug was well-tolerated by participants. Clinical data revealed a significant 11.85-point reduction on the Liebowitz Social Anxiety Scale (LSAS) compared to the placebo group. Notably, the responder rate for those treated with EMP-01 reached 49%, significantly higher than the 15% observed in the placebo group. These results mark a critical milestone for the company, as the trial demonstrated efficacy without the need for adjunctive psychotherapy. Investors view this development as a major step forward in the company's biotech pipeline, potentially increasing the probability of future regulatory success.